Leucine.

A small fraction of leucine is converted in the body to HMB, the metabolite that carries much of leucine's signal to slow muscle protein breakdown. Supplying both covers the mTOR side from leucine and the breakdown side from HMB without depending on that low conversion rate.

Leucine, valine and isoleucine share the LAT1 transporter and the same branched-chain aminotransferase, so large isolated leucine doses lower circulating valine and isoleucine. Formulating them together keeps the branched-chain pool balanced rather than letting one crowd out the others.

Branched chain aminotransferase needs pyridoxal phosphate to move leucine's amino group onto alpha-ketoglutarate. That transamination is the entry point to leucine catabolism.

Thiamine pyrophosphate is required by the branched chain ketoacid dehydrogenase complex. Without it leucine's ketoacid accumulates instead of being oxidised.

Riboflavin derived FAD serves both the dehydrogenase complex and the acyl-CoA dehydrogenase further along leucine breakdown. Flux through those steps tracks riboflavin status.

Lipoamide is the bound cofactor on the E2 subunit of branched chain ketoacid dehydrogenase and shuttles the acyl group. It plays the same role here as in pyruvate dehydrogenase.

Pantothenate builds the coenzyme A that carries isovaleryl-CoA and HMG-CoA through leucine catabolism. The pathway needs CoA at every acyl step.

3-methylcrotonyl-CoA carboxylase, unique to the leucine branch, is biotin dependent. Biotin status is what keeps that carboxylation moving.

Leucine enters the cell on the LAT1 antiporter driven by glutamine efflux, so glutamine availability sets intracellular leucine. Glutamine also accepts the nitrogen released when leucine is transaminated.

Both use the same large neutral amino acid carrier into the brain, so a leucine load reduces central tryptophan entry. This is the long established branched chain interaction.

Tyrosine and leucine compete at LAT1 for passage across the blood brain barrier. Dosing them together lowers how much tyrosine arrives centrally.

Nitrogen removed from leucine in muscle leaves mainly as alanine and glutamine via the glucose-alanine cycle. Alanine is the carrier for that nitrogen rather than a rival for transport.

Leucine, isoleucine and valine share the LAT1 transporter and the branched-chain aminotransferase and dehydrogenase complex that degrades all three. A large isolated leucine dose therefore drives its own catabolism and lowers plasma isoleucine and valine. That is the biochemical reason branched-chain products are usually sold as a ratio rather than as leucine alone. The source index flags isoleucine as antagonistic to leucine in co-occurrence, consistent with this competition.

Large neutral amino acids compete for the same carrier at the intestinal wall and at the blood-brain barrier. A large leucine dose lowers the fraction of phenylalanine, tyrosine and tryptophan crossing at the same time. The competition is dose-dependent and short-lived.

Whey already supplies roughly a tenth of its amino acids as leucine, which is why a normal serving crosses the threshold that activates muscle protein synthesis signalling. Added leucine raises that peak further and is used mainly to bring a lower-leucine protein up to it. Adding leucine to a serving that already clears the threshold gives less additional signal.

Casein clots in the stomach and releases amino acids slowly, producing a flatter and lower leucine peak than whey. Leucine is sometimes added to a casein serving to restore the sharp early rise while keeping the slow tail. The rationale is kinetic and is drawn from amino acid absorption profiles rather than from a head-to-head outcome trial.

Collagen is dominated by glycine, proline and hydroxyproline and carries very little leucine, so a collagen serving on its own does not reach the leucine level associated with the muscle protein synthesis signal. Where a formula uses collagen as the protein source, added leucine is what supplies that missing fraction. The two cover different gaps rather than doing the same job.

Creatine works on phosphocreatine resynthesis and short-duration power output, leucine on the anabolic signalling that follows a training session. Combining them targets separate steps of the same training response. This is mechanistic complementarity, not a measured additive effect size.

Long-chain omega-3 fatty acids incorporate into muscle membrane phospholipids and have been studied for their effect on the muscle protein synthesis response to amino acids. Leucine supplies the trigger, the fatty acids alter the membrane environment the signal runs through. Read it as mechanistic; no combination measurement is cited on this page.

Taurine and leucine appear together with ketone salts and caffeine in an endurance performance trial, so their co-administration is documented rather than hypothetical. The trial tested the whole blend, so no leucine-specific contribution can be separated out. The rows for the blend are reported as blend results.

A randomised crossover trial gave ketone salts with caffeine, taurine and leucine and reported an improvement in endurance performance with the caffeine-containing arm that was not seen without it. Leucine was present in both arms, so the trial does not isolate what leucine contributed. The pairing is documented co-administration.

Arginine is the substrate for nitric oxide synthesis and a urea cycle intermediate, while leucine acts as a signalling amino acid. The source index flags arginine among antagonistic co-occurrences with leucine, which likely reflects competing transport rather than a functional conflict. Both belong in the same sports formulas and the interaction is described mechanistically.

Lysine and leucine appear together in the co-study index with an antagonism flag, consistent with the long-recognised competition between cationic and neutral amino acids at shared intestinal carriers. Large single doses of one can lower the simultaneous uptake of the other. Mixed amino acid blends and food protein avoid the problem by keeping any single amino acid dose modest.